http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-E031091-T2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8f3fc0bcee25a1161415431ccb1faf7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
| filingDate | 2009-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a09c23ea1623ed803daabdd5a321950 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9601050ba5766deaabe51083a8abcc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_668e8a2d8d56c8e0abc2141542bf898f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_688a8bd8aeff233f2888b88cbf320b05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02f9be74703a2dc7948685308b9a0407 |
| publicationDate | 2017-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-E031091-T2 |
| titleOfInvention | A method for preparing a pharmaceutical composition for a contrast agent |
| abstract | The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, said macrocyclic chelate being DOTA and said lanthanide being gadolinium, said process comprising the following successive steps: nb) preparing a liquid pharmaceutical composition containing: n- the complex of macrocyclic chelate with a lanthanide, n- free macrocyclic chelate that is not under the form of an excipient X[X',L] in which L is the macrocyclic chelate and X and X' are a metal ion, in particular chosen independently from calcium, sodium, zinc and magnesium, and/or n- free lanthanide, nwherein the amounts of free macrocyclic chelate and of free lanthanide added are such that there is an excess free macrocyclic chelate or an excess free lanthanide, nc) measuring, in the pharmaceutical formulation obtained in step b), the concentration of free macrocyclic chelate C ch l and/or free lanthanide C lan l ; nd) adjusting C ch l and of C lan l so as to obtain C lan l = 0 and to obtain C ch l = Ct ch l , wherein Ct ch l is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is selected in the range of between 0.002 % and 0.4 % mol/mol, said adjustment of C ch l and of C lan l being performed n- if Clan l > 0 and/or C ch l < Ct ch l , by adding free macrocyclic chelate and/or by eliminating free lanthanide by passing through an ion-exchange resin and/or by modifying the pH, n- if C lan l = 0 and C ch l > C t ch l , by eliminating free macrocyclic chelate and/or by adding free lanthanide and/or by modifying the pH, nwherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate DOTA-Gd in the final liquid pharmaceutical formulation in mol/mol. |
| priorityDate | 2008-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.